Previous Article | Next Article 
Molecular and Cellular Biology, May 1999, p. 3529-3539, Vol. 19, No. 5
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
The Tmp Gene, Encoding a Membrane
Protein, Is a c-Myc Target with a Tumorigenic Activity
Ittai
Ben-Porath,
Ofra
Yanuka, and
Nissim
Benvenisty*
Department of Genetics, Institute for Life
Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
Received 29 June 1998/Returned for modification 1 September
1998/Accepted 15 February 1999
 |
ABSTRACT |
The c-Myc oncoprotein induces cell proliferation and transformation
through its activity as a transcription factor. Uncovering the genes
regulated by c-Myc is an essential step for understanding these
processes. We recently isolated the tumor-associated membrane protein
gene, Tmp, from a c-myc-induced mouse brain
tumor. Here we show that Tmp is specifically highly
expressed in mammary tumors and T-cell lymphomas which develop in
c-myc transgenic mice, suggesting that Tmp
expression is a general characteristic of c-Myc-induced tumors. In
addition, Tmp expression is induced upon serum stimulation of fibroblasts as shown in a time course closely correlated with c-myc expression. We have isolated the Tmp
promoter region and identified a putative c-Myc binding element,
CACGTG, located in the first intron of the gene. We show
here that constructs containing the Tmp regulatory region
fused to a reporter gene are activated by c-Myc through this
CACGTG element and that the c-Myc-Max protein complex can
bind to this element. Moreover, an inducible form of c-Myc, the MycER
fusion protein, can activate the endogenous Tmp gene. We
also show that Tmp-overexpressing fibroblasts induce rapidly growing tumors when injected into nude mice, suggesting that
Tmp may possess a tumorigenic activity. Thus, TMP, a member of a novel family of membrane glycoproteins with a suggested role in
cellular contact, is a c-Myc target and is possibly involved in
c-Myc-induced transformation.
 |
INTRODUCTION |
The c-Myc oncoprotein is a key
regulator of cell growth and differentiation and is implicated in a
variety of human tumors (30, 45, 48). c-Myc activity is
associated with cell proliferation, and the expression of c-Myc can
drive quiescent cells into S phase (15, 24). A role for
c-Myc in the induction of apoptosis has also been established (27,
28).
c-myc encodes a basic helix-loop-helix leucine zipper
(bHLH-LZ) protein, which heterodimerizes with the ubiquitous Max
protein to form a nuclear transcription factor (54). A
number of target genes for c-Myc transcriptional activation have been
identified in recent years (reviewed in references 21,
30, and 34). The data regarding these
genes do not, as yet, provide a clear understanding of the mechanisms
of c-Myc activity, although initial attempts have been made to
categorize the target genes into functional classes, either according
to their cellular functions or to the c-Myc-related processes in which
they appear to function (21, 30, 34). A role for c-Myc as a
transcription repressor has also been suggested, and a number of
negatively regulated genes have been described (30).
The c-Myc-Max complex activates transcription through a specific E-box
hexamer, CACGTG, which acts as a binding site (11, 12), although binding to additional sequences, mainly to
CATGTG, has also been observed (10, 35). In known
c-Myc targets this binding site is typically located downstream to the
transcription start site, most commonly in the first intron or in the
5'-untranslated region (7, 34).
We have recently isolated and characterized the Tmp
(tumor-associated membrane protein) gene from mice and humans
(5). Tmp was initially isolated from a cDNA
library of a brain tumor which developed in a mouse transgenic for
c-myc (7, 8). The gene was found to be highly
expressed in the tumor but not in normal tissue (5).
Tmp expression is associated with cell proliferation; it is
highly expressed in proliferating fibroblasts but is downregulated when
these cells are growth arrested (5). Tmp is also
highly expressed in undifferentiated proliferating embryonic stem
cells, but a much lower expression is observed after these cells are
induced to differentiate (5). In both systems,
Tmp expression closely correlates with that of
c-myc. Tmp cDNAs from different mammals were
isolated in parallel by several other groups (47, 57, 59,
69).
Tmp encodes a putative membrane glycoprotein of 160 amino
acids, with four transmembrane domains. It is homologous to the Pmp22/Gas3 gene, which is involved in several human
hereditary peripheral neuropathies (16, 51).
Pmp22/Gas3 was initially characterized as a
growth-arrest-specific gene, one upregulated in serum-starved
fibroblasts (44). It thus displays an expression pattern
inverse to that of Tmp in these cells (5).
Overexpression of Pmp22/Gas3 in cultured cells can delay
cell cycle progression and lead to apoptosis (29, 73, 74).
The cellular function of PMP22 is, however, largely unknown,
although a role in cell adhesion has been suggested (65).
Recently, two additional novel genes, which are homologous to
Tmp and PMP22, were identified both in mice and
humans, and were named XMP/EMP2 and
YMP/EMP3/HNMP-1 (5, 6, 13, 68). The four genes,
Tmp, Pmp22, Xmp, and Ymp,
thus define a novel gene family encoding membrane glycoproteins and are
possibly involved in cellular contact.
The Tmp expression pattern, together with the fact that this
gene was cloned from a c-myc-induced tumor, suggested that
Tmp is a potential target for c-Myc activation. This is
further supported here by the finding that high Tmp
expression is a characteristic of Myc-induced tumors in the mouse. We
present evidence that Tmp is a transcriptional target for
c-Myc and that it may possess a tumorigenic activity.
 |
MATERIALS AND METHODS |
Cell lines and media.
NIH 3T3 and Rat1 cells were grown in
Dulbecco modified Eagle medium supplemented with 50 U of penicillin per
ml, 50 µg of streptomycin per ml, and 2 mM glutamine. Fetal calf
serum (FCS; 10%) (Biological Industries) was added for cells in
proliferation conditions, and 0.1% FCS was used for serum-starved
cells. For growth induction assays, cells were grown to subconfluency,
serum starved for 3 days, and then induced to proliferate with
serum-rich medium. Rat1 cells stably transfected with the
Tmp gene were grown in medium containing 200 µg of G418
per ml. Rat1 cells expressing the MycER and
106-143MycER constructs
were kindly provided by Linda Z. Penn (46). The cells were
grown in minimum essential medium (alpha modified) with the above
supplements and 5 µg of puromycin per ml. For MycER induction
experiments, cells were grown to confluency and serum starved for 3 days; then 100 nM 4-hydroxytamoxifen (4-OHT) was added to the medium.
In cycloheximide experiments, 10 µg of cycloheximide per ml was added
to the medium together with 4-OHT.
RNA extraction and Northern blot hybridization.
Total RNA
from cells and tumors was extracted with a guanidium thiocyanate-phenol
mixture as described previously (18). Northern blot
hybridization was performed according to standard procedures with
formaldehyde-containing gels and formamide-based hybridization
solutions (58). Probes were radiolabeled by random priming
(58).
Isolation of genomic clones and genomic structure analysis.
A mouse 129SVJ genomic library (Stratagene 946309) was screened with
Tmp cDNA probes by standard procedures (58). The
exon-intron structure was determined by sequencing and PCR with primers
from within the cDNA. Sequencing of the Tmp regulatory
region was performed by using an ABI automated sequencer according to
standard procedures. Primer extension analysis of the Tmp
transcript was performed with 1 µg of poly(A)+ RNA
extracted from the BK-1 cell line, which is derived from a
c-myc-induced brain tumor (7). A 1-ng portion of
the primer described below (see Fig. 3B) was 32P end
labeled and hybridized with the mRNA in the presence of KCl (133 mM).
Avian myeloblastosis virus reverse transcriptase was used for the
extension reaction under standard conditions (58).
Construction of chimeric genes and expression vectors.
To
create chimeric Tmp-CAT constructs (see Fig. 4A, construct a), an
~5-kb AccI fragment encompassing the Tmp
promoter region, exon 1, and ~3 kb of intron 1, including the
CACGTG element, was cloned into the AccI site of
the pCAT-Basic Vector (Promega E1041). A 1.5-kb
BbrpI-SmaI fragment was excised from construct a,
beginning at the CACGTG element and extending to the 3' end
of the original fragment, to create construct b. Construct c was
created by inserting a point mutation in the CACGTG element
in construct a. Vectors were restricted with BbrpI, which
cuts in the unique CACGTG element. A terminal transferase
reaction was performed on the linearized plasmid by using
Taq polymerase and dATP+dTTP nucleotides, and the vectors
were then religated and restricted with BbrpI. Bacteria were
transformed with the total reaction mix, and the colonies were
analyzed. For the construction of the Tmp expression vector, a BamHI-XhoI 850-bp cDNA fragment encompassing
the full coding sequence of the mouse Tmp gene was cloned
into the corresponding sites of the pCA1038 expression vector
(71), which contains the phosphoglycerate-kinase-1 (PGK1)
promoter and poly(A) signal. Plasmid PGK-neo (71) was used
as a selection marker for stable transfections.
Transfection conditions and CAT assays.
For chloramphenicol
acetyltransferase (CAT) assays, NIH 3T3 cells were transiently
transfected with the described Tmp-CAT constructs. c-Myc activation was
studied by cotransfection with the pSV2-myc expression vector
containing the wild-type human c-myc. Transient
transfections were performed by electroporating cells at 960 µF and
260 V, as described previously (53), with 20 µg of plasmid
DNA. The pCAT-Basic vector was used as a negative control, and the
pSV2-CAT vector was used as a positive control. The pSV2-neo vector was
used to control for promoter competition. Cells were harvested 48 h after transfection, and a CAT activity assay was performed according
to standard procedures (33). To control for transfection
efficiency, plasmid DNA was extracted from transfected cells by lysis
in Tris-EDTA buffer containing 0.6% sodium dodecyl sulfate (SDS).
Genomic DNA was precipitated in the presence of 1 M NaCl. Supernatants
were treated with proteinase K, followed by phenol extraction and
ethanol precipitation. Samples were dot blotted and hybridized with a
CAT probe. Stable transfections were performed by calcium
phosphate-DNA coprecipitation in HEPES buffer (pH 6.95)
(17). Rat1 cells were cotransfected with 40 µg of the
PGK-Tmp plasmid and 1 µg of the PGK-neo plasmid as a selection
marker. Resistant colonies were selected in medium containing 400 µg
of G418 per ml.
Electrophoretic mobility shift assays.
A double-stranded
oligonucleotide of the sequence
5'-ACAAACCCACGTGCTAAATGC-3', representing the
Tmp CACGTG sequence and flanking nucleotides, was
radiolabeled by a fill-in reaction with [32P]dCTP. A
mutant form of the oligonucleotide containing a CTCGAG element with identical flanking nucleotides served as a control. The labeled oligonucleotide was incubated with purified recombinant maltose-binding protein (MBP)-Myc and MBP-Max proteins, which were
kindly provided by Thanos D. Halazonetis (22). These contain either the bHLH-LZ region of human c-Myc (amino acids 346 to 439) or
the bHLH-LZ region of Max (amino acids 7 to 114) fused to MBP. Concentrations of recombinant proteins were determined by size separation by SDS-polyacrylamide gel electrophoresis (PAGE) and comparison to known bovine serum albumin (BSA) reference
concentrations. Protein (10 to 50 ng) was used in the reactions as
indicated. Incubation was performed in 100 mM HEPES buffer (pH 7.9), 10 mM MgCl2, 5 mM dithiothreitol, 2.5 mM EGTA, 40 mM KCl, and
1.5 mg of BSA per ml, with 2 µg of poly(dI-dC), in a final volume of 25 µl for 30 min at room temperature. For the competition assays, unlabeled oligonucleotide, either wild type or mutant, was added in a
25- or 100-fold molar excess to the mixture. The reaction mixture was
run on a 6% polyacrylamide gel in 0.5× Tris-borate-EDTA buffer,
dried, and subjected to autoradiography for 16 h.
Tumor growth assays.
Four clones of Rat1 cells expressing
the PGK-Tmp expression vector and four clones expressing only the
PGK-neo selection marker were used for injection. Cells
(~107), suspended in 200 to 400 µl of
phosphate-buffered saline, were injected subcutaneously into athymic
nude (nu/nu) mice as described previously (20).
Animals were monitored at least twice a week for the appearance and
measurement of tumors.
 |
RESULTS |
Tmp is highly expressed in tumors induced by
c-myc in transgenic mice.
Tmp was initially
isolated from a brain tumor that developed in a mouse that was
transgenic for c-myc (5, 7). To examine whether
high Tmp expression is a general phenomenon in
c-myc-induced tumors, we tested Tmp expression in
several cell lines derived from adenocarcinomas of the mammary gland,
which developed in mice transgenic for c-myc
(63), c-neu (50), or
v-Ha-ras (14). These lines present an excellent
experimental system because the development of the tumor can be
ascribed primarily to the expression of a specific oncogene.
Impressively, the highest expression levels of Tmp were
observed in c-myc-induced mammary tumors; these levels were
approximately 10- to 20-fold higher than in normal mammary gland and
epithelium (Fig. 1A). In
c-neu-induced mammary tumors, Tmp was also
expressed at higher levels than in the normal tissues but to a much
lower extent (Fig. 1A). The level of Tmp expression in
v-Ha-ras-induced mammary tumors was equal to or lower than that in the normal tissues (Fig. 1A).

View larger version (65K):
[in this window]
[in a new window]
|
FIG. 1.
Tmp is specifically expressed in
c-myc-induced tumors. (A) Northern blot hybridization was
performed on poly(A)+ RNA from normal mammary gland and
epithelium and from cell lines derived from adenocarcinomas of the
mammary gland, which developed in mice transgenic for
v-Ha-ras, c-neu, or c-myc
(26). Each lane contains RNA from a different cell line. Ex.
c-myc, exogenous transcript from transgene; End.
c-myc, endogenous transcript. (B) Northern blot
hybridization was performed on total RNA from cell lines of mammary
tumors which developed in mice transgenic for NDF or for
both NDF and c-myc (39). (C) Northern
blot hybridization was performed on poly(A)+ RNA from cell
lines derived from T-cell lymphomas, which developed in
p53 / mice and in c-myc transgenic
mice (25). Hybridizations were performed with
Tmp, Gapdh, and 28S rRNA probes, as indicated.
|
|
We also examined the expression of
Tmp in cell lines from
mammary tumors that developed in mice transgenic for the Neu
differentiation
factor gene (
NDF) or for both
NDF
and c-
myc (
39).
Tmp expression
was
detected in all tumors but was significantly higher in tumors
from mice
transgenic for both genes (Fig.
1B).
The correlation between c-
myc and
Tmp expression
was also observed in T-cell lymphoma cells. We compared
Tmp
expression in
cell lines derived from lymphomas which developed in
c-
myc transgenic
mice and in mice homozygous for a null
mutation in the
p53 gene
(
25). Once again, a
higher level of
Tmp expression was observed
in
c-
myc-induced lymphomas than in p53
/
lymphomas (Fig.
1C). Thus,
Tmp is highly expressed in at
least
three different types of tumors induced by c-Myc in the mouse,
suggesting that it is activated in the c-Myc-induced tumorigenic
pathway.
Tmp expression is induced in serum-stimulated
cells.
We have previously reported that Tmp expression
is high in dividing cells but much lower in quiescent cells, a finding
correlating c-myc expression (5). We studied the
time course of Tmp activation in Rat1 cells after growth
stimulation by serum. Activation of Tmp transcription was
seen as early as 2 h after serum stimulation, and expression
peaked after 3 h (Fig. 2). This time
course closely matches that of c-myc in these cells, showing
a rise in c-myc expression that is observed as early as
1 h after stimulation and lasting 2 to 3 h (Fig. 2).
Tmp expression thus follows the characteristic activation
pattern of c-Myc during the G0-to-G1 transition. It is noteworthy that Tavtigian et al. (67)
isolated a transcript designated I-8-9, later identified by us as
Tmp, in a screen for mid-G1 serum response genes
(67).

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 2.
Tmp activation in serum-stimulated cells. (A)
Rat1 fibroblasts were grown in low-serum conditions for 3 days and then
transferred to a high-serum medium. Total RNA was extracted at
indicated time points. Northern blot hybridizations were performed with
Tmp, c-myc, and 18S rRNA probes. (B) Quantitation
of Tmp and c-myc activation levels, calculated by
comparison to 18S rRNA levels and normalized relative to the expression
level at the time of serum stimulation.
|
|
Isolation of the genomic Tmp gene and analysis of the
promoter region.
To isolate Tmp genomic clones and
analyze the Tmp promoter region, we screened a 129SVJ mouse
genomic DNA library with cDNA probes encompassing the entire
Tmp transcript. Four genomic clones were isolated and
analyzed. We determined the exon-intron boundaries of the
Tmp gene by using sequencing and PCR performed with primers from within the cDNA sequence. Our analysis indicated that
Tmp is composed of five exons (Fig.
3A). Exons 2 to 5 contain the coding
region and a 3'-untranslated region of 2.1 kb, as has been previously
reported by Lobsiger et al. (43). One of the isolated genomic clones contained the Tmp promoter region and exon 1. Exon 1 contains most of the 5'-untranslated region and is separated from exon 2 by an intron of at least 10 kb. The genomic structure of
Tmp is similar to that of its homolog Pmp22.
Pmp22 is also composed of 5 exons, of similar sizes, which encode
corresponding regions of the homologous protein (43, 66).

View larger version (44K):
[in this window]
[in a new window]
|
FIG. 3.
Genomic structure of Tmp and sequence of the
Tmp regulatory region. (A) Tmp is composed of
five exons, which are marked by differently shaded gray boxes. Exon 1 contains most of the 5' untranslated sequence. Exons 2 to 5 contain the
480-bp coding sequence, which is marked by wide boxes. The codons of
the TMP protein encoded by each exon are indicated by numbers in the
protein diagram. The lines in the protein diagram represent the
membrane, and a putative glycosylation site is marked on the first
outer loop. (B) Sequence of the Tmp regulatory region. The
start site of transcription as determined by primer extension is marked
by an arrow. An asterisk marks a possible alternative start site
corresponding to the asterisk-marked product in panel C. Putative TATA
boxes are marked by a rectangles. The primer used for primer extension
is marked by a dashed arrow. The CACGTG element is marked by
a black background. AP-1 binding elements are marked by a thick line,
and the poly(T) element is marked by a thin line. ex1, exon1; in1,
intron1. GenBank accession number, AF055577. (C) Determination of the
transcription start site. A primer extension reaction was performed
with the primer indicated in panel B on RNA from a
c-myc-induced brain tumor cell line used as a template.
Products were run on a 4% polyacrylamide gel in parallel with a
sequencing reaction of the genomic region, which was initiated with the
same primer. The prominent product, 63 bases long, is marked by an
arrow. An asterisk marks a product corresponding in size to a
previously published cDNA sequence (43).
|
|
We determined the sequence of approximately 1.6 kb of the
Tmp genomic region, including the promoter region, exon 1, and part
of intron 1 (Fig.
3B). To determine the start site of
transcription,
we performed a primer extension assay, with a primer
from the
3' region of exon 1, as determined from the cDNA sequence and
from genomic analysis. A prominent band, 63 bases long, was detected
(Fig.
3C, arrow), representing a putative start site at an adenine
residue marked 1 (Fig.
3B). A putative TATA box (TATAA) is located
at
position

30 relative to this site. However, as shown, there
are
additional minor bands in this region (Fig.
3C). Interestingly,
a cDNA
sequence extending to position

60 has been previously
published
(
43). We detected a minor band corresponding to exactly
this
point (Fig.
3C, asterisk), suggesting that this is an alternative
start
site. This would be supported by the finding of an additional
putative
TATA box (TTTAAAA) 31 bp upstream of this point. The
sequences of both start sites conform to the start site consensus:
an
adenine residue preceded by a cytosine and surrounded by pyrimidine
residues (
19).
Two putative AP-1 binding elements (
41) are located at
positions

245 to

237 and

108 to

100. In addition, a poly(dT)
tract, 29 residues long, is located at position

147 to

119.
This
element is common in yeast promoters (
36) and has recently
also been detected in mammalian promoters and shown to be a functional
transcription promoting element (
72).
A putative c-Myc binding element, namely, a canonical CACGTG
E-box, was found in intron 1, approximately 1.1 kb downstream
of
the start site of transcription (Fig.
3B). This position is
analogous
to the position of functional c-Myc binding sites identified
to date
(
9,
34). In known c-Myc targets, the binding site
is
typically located downstream of the start site of transcription,
most
commonly either in the 5'-untranslated region or in intron
1. The
location of the CACGTG element in
Tmp thus
suggested that
it may be a functional c-Myc binding element and that
Tmp transcription
is directly regulated by c-Myc.
c-Myc activates the Tmp promoter.
To test the
activity of the Tmp promoter, we prepared several chimeric
constructs in which the Tmp regulatory region was placed upstream of the CAT reporter gene (Fig.
4A). A Tmp fragment containing the promoter, exon 1, and a part of intron 1 including the c-Myc binding element, was cloned upstream to the CAT gene (Fig.
4A, construct a). This construct induced a low level of CAT activity when transfected into NIH 3T3 cells (Fig. 4B). Construct b was created
by excising a fragment containing the CACGTG element from construct a. No CAT activity was observed upon transfection of this
construct (Fig. 4B), indicating that an element, or elements, contained
in the excised fragment, among them possibly the CACGTG element, are necessary for Tmp promoter activity.

View larger version (51K):
[in this window]
[in a new window]
|
FIG. 4.
Activation of the Tmp promoter by c-Myc. (A)
Schematic representation of Tmp-CAT constructs. Construct a contains a
5-kb fragment from the Tmp regulatory region cloned upstream
of the CAT reporter gene. In construct b a 1.5-kb fragment containing
the CACGTG element and the downstream region of intron 1 was
excised from construct a. In construct c, a point mutation was
introduced into the CACGTG element. (B) Activity of
Tmp promoter. NIH 3T3 cells were transfected with Tmp-CAT
construct a or b, and the CAT activity was studied. Activity was
observed only upon transfection with construct a. C, free
chloramphenicol; 1AC and 3AC, 1- and 3-acetylated forms of
chloramphenicol, respectively. (C) c-Myc activates the Tmp
promoter. Cells were cotransfected with Tmp-CAT construct a and with
either the pSV2-myc expression vector or the pSV2-neo vector as a
control. (D) The integrity of the CACGTG element is
necessary for Tmp promoter activity and c-Myc activation.
Cells were transfected with Tmp-CAT construct a or c, with or without
the pSV2-myc vector. (E) Histogram bars represent the mean CAT
activities from four to seven experiments ± the standard error.
The results are presented relative to the activity level of Tmp-CAT
construct a.
|
|
We wished to test whether c-Myc can transcriptionally activate the
Tmp promoter and whether the CACGTG element plays
a role
in this activation. Cotransfection of the pSV2-myc expression
vector with Tmp-CAT construct a into NIH 3T3 cells resulted in
an
increase in CAT activity (Fig.
4C and D). An average 2.3-fold
increase
in activity was observed in seven experiments (Fig.
4E).
We introduced
a point mutation into the element in the original,
active, construct a,
changing its sequence from CACGTG to
CAC
TAGTG,
thus creating construct c. This
mutation resulted in a significant
reduction of CAT activity induced by
the
Tmp promoter (Fig.
4D
and E), indicating that the
CACGTG element is a functional transcription-promoting
element that is necessary for
Tmp promoter activity. When
the
pSV2-myc vector was cotransfected with construct c, no increase
in
CAT activity was detected (Fig.
4D and E), suggesting that
c-Myc
activation is mediated through this
element.
These results suggest that the CACGTG sequence in intron 1 of
Tmp is a functional transcription-promoting element and
that
c-Myc can activate the
Tmp promoter through this
element.
The c-Myc-Max complex can bind the CACGTG element found
in Tmp.
To test whether the c-Myc-Max complex can bind the
CACGTG element found in intron 1 of Tmp, we
performed an electrophoretic mobility shift assay. A labeled
double-stranded oligonucleotide containing the CACGTG
element and flanking nucleotides from the Tmp intron 1 sequence was incubated with purified recombinant truncated c-Myc and
Max proteins. These proteins contain the bHLH-LZ region of either c-Myc
or Max, fused to MBP. Incubation with both proteins resulted in a
strong shifted band of the labeled oligonucleotide (Fig.
5A). The intensity of the shifted band
was increased with increasing c-Myc/Max ratios (0.5:1, 1:1, and 2.5:1)
(Fig. 5A). Incubation with c-Myc alone did not produce a shifted band,
while incubation with Max alone produced a weak shifted band (Fig. 5A). Since the MBP-Myc and MBP-Max proteins used in this assay are of
similar molecular sizes (Fig. 5B), Max-Max and c-Myc-Max complexes cannot be distinguished by size. However, a 1:1 ratio of c-Myc-Max proteins produced a much stronger shifted band than that observed with
Max alone (7.6 [±0.7]-fold increase, average of three experiments), a finding consistent with the known increased DNA binding activity of
c-Myc-Max complexes (3). This indicates that both proteins are probably present in the complexes. Incubation of c-Myc and Max
proteins with the labeled oligonucleotide in the presence of an
unlabeled competitor oligonucleotide resulted in a significant reduction of the labeled shift, while no reduction was observed upon
incubation with an unlabeled competitor oligonucleotide carrying a
mutated Myc binding element, CTCGAG (Fig. 5A). Incubation of c-Myc and Max proteins with a labeled mutated oligonucleotide did not
result in a shifted band (Fig. 5A), indicating the specificity of the
binding.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 5.
The c-Myc-Max complex binds the CACGTG
element in Tmp. (A) A labeled, 21-bp oligonucleotide
containing the CACGTG element and flanking nucleotides from
intron 1 (Tmp-WT) or an identical oligonucleotide carrying a mutated
element, CTCGAG (Tmp-mut), was incubated with purified
recombinant MBP-Myc and MBP-Max proteins containing the bHLH-LZ region
of either c-Myc or Max fused to MBP. Binding was tested by
electrophoretic mobility shift assay of the labeled oligonucleotide.
Where indicated, 20 ng of each protein was used, except under the
diagonal bar, where increasing concentrations of MBP-Myc protein were
used as follows: 10, 20, and 50 ng. Unlabeled competitor
oligonucleotide, either Tmp-WT or Tmp-mut, was used in 25× and 100×
molar excess, as indicated, of labeled Tmp-WT. (B) MBP-Myc and MBP-Max
proteins as they appear on SDS-PAGE gel. The numbers indicate the
molecular masses of ladder proteins in kilodaltons.
|
|
Tmp is activated by the MycER fusion protein.
We
utilized the MycER-inducible system to test the ability of c-Myc to
upregulate Tmp expression. The MycER construct produces a
fusion protein of c-Myc and the estrogen receptor ligand-binding domain
(24). We used the MycER version of the construct, which carries a G252R mutation in the TAF-2 transcription-activating domain
of the estrogen receptor (42). The transcriptional activity of the MycER product is specifically induced by 4-OHT. Rat1 cells expressing either the wild-type MycER or the transcriptionally inactive
deletion mutant
106-143MycER (46) were cultured in low-serum conditions for 3 days, after which 4-OHT was added to the
medium. A two- to threefold increase in Tmp expression was observed within 3 h of the induction of the MycER cells (Fig. 6A). Tmp expression in the
106-143MycER cells was unaffected by the addition of 4-OHT (Fig.
6A), indicating that a transcriptionally active c-Myc protein is
required for Tmp activation. This mutant form of the c-Myc
protein has also been characterized as deficient in transformation
activity (64). The transcription of the endogenous Tmp gene is thus upregulated when c-Myc activity is induced,
supporting the hypothesis that it is a direct c-Myc target. The time
course and level of upregulation are similar to those found for other c-Myc targets which were tested in this system (31, 35, 70).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 6.
Tmp expression is induced by the MycER fusion
protein. (A) Rat1 cells expressing either the wild-type MycER or
deletion mutant 106-143MycER (42, 46) were serum starved
for 3 days. 4-OHT was added to the medium, and total RNA was extracted
at different time points. Northern blot hybridizations were performed
with a Tmp probe and with a probe for the
glyceraldehyde-3-phosphate dehydrogenase (Gapdh) gene. The
histogram represents Tmp expression relative to
Gapdh expression, as determined by densitometry. Results
were normalized relative to the expression level at the time of the
addition of 4-OHT. (B) The experiment in panel A was repeated in the
presence of cycloheximide (CHX) and with cycloheximide alone. The
histogram represents Tmp expression relative to
Gapdh expression.
|
|
Tmp activation was also observed when MycER cells were
treated with 4-OHT in the presence of the protein synthesis inhibitor
cycloheximide (Fig.
6B). This finding is consistent with the suggestion
that
Tmp is activated directly by c-Myc in a way that is
independent
of protein synthesis. Cycloheximide alone also caused an
elevation
of
Tmp mRNA levels (Fig.
6B), as was observed for
several other
c-Myc targets in which this issue was addressed (
35,
70).
Yet, the fact that
Tmp induction by MycER is
observed in the presence
of cycloheximide and that it is higher than
the induction observed
with cycloheximide or 4-OHT alone (Fig.
6B)
supports the notion
that
Tmp is a direct target for c-Myc
activity.
Cells overexpressing the Tmp gene are tumorigenic in
nude mice.
To examine the effects of Tmp
overexpression, a vector containing the mouse Tmp gene under
the control of the PGK1 promoter was transfected into Rat1 fibroblasts.
These cells express the endogenous Tmp gene when they are
proliferating, and expression is downregulated during growth arrest
(Fig. 2A and Fig. 7A). Four clones stably
expressing the exogenous transfected Tmp gene were isolated
(Fig. 7A). The level of expression in these cells is ca. two- to
threefold higher than in control cells (Fig. 7A).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 7.
Tmp-overexpressing cells are tumorigenic in
nude mice. (A) Rat1 fibroblasts were cotransfected with the PGK-Tmp and
the PGK-neo constructs. Total RNA was extracted from G418 resistant
colonies, and Northern blot hybridization was performed with a
Tmp probe, thereby detecting both endogenous (End.) and
exogenous (Ex.) transcripts (2.7 and 1.2 kb, respectively), and with a
-actin probe. Examples of three positive clones (lanes b,
c, and d) and two negative clones (lanes a and e) are shown. (B) Cells
from four PGK-Tmp-expressing clones (Tmp1 to Tmp4) and four clones
expressing only the PGK-neo selection marker (con1 to con4) were
injected subcutaneously into athymic nude mice. The graphs display the
tumor volumes at various times after injection for PGK-Tmp-expressing
cells (top panel) and for control cells (bottom panel).
|
|
To test whether
Tmp overexpression increases the degree of
tumorigenicity of these cells, cells from four different PGK-Tmp
clones
and from four different control clones expressing only
the neo
resistance selection marker were injected subcutaneously
into nude
mice. Cells from three of the four PGK-Tmp clones resulted
in rapidly
developing subcutaneous tumors in all injections (Fig.
7B). In total,
tumors developed as a result of 7 of 9 injections
of these cells. Of
the control cells, tumors developed in only
two of seven injections,
and these appeared relatively late after
injection (Fig.
7B). These
results thus suggest that overexpression
of
Tmp can enhance
the tumorigenicity of Rat1 cells and that
Tmp may possess a
function which can contribute to the transformation
process.
 |
DISCUSSION |
To understand the mechanisms by which c-Myc induces cells to
proliferate and by which it can lead to malignant transformation, it is
essential to identify the genes regulated by c-Myc. In this study, we
establish, based on the following evidence, that the Tmp
gene is directly activated by c-Myc. (i) Tmp carries a
putative c-Myc binding element located in the first intron, a typical
location for this element in c-Myc targets. (ii) The Tmp
promoter can activate a reporter gene, depending on the integrity of
the CACGTG element, indicating that this is a functional
element. (iii) c-Myc can activate the Tmp promoter when
cotransfected into cells, and this activation is mediated by the c-Myc
binding element. (iv) The c-Myc-Max protein complex can bind the
CACGTG element. (v) The endogenous Tmp gene is
activated when MycER transcriptional activity is induced, and this
occurs also in the absence of protein synthesis.
Furthermore, the Tmp expression pattern in several cellular
systems is closely correlated with that of c-myc. Tmp is
expressed in proliferating fibroblasts but is downregulated when these
cells are quiescent. When cells are serum stimulated to progress from G0 to G1, Tmp is strongly activated,
as shown by a time course that closely matches that of c-myc.
Tmp is expressed in nondifferentiated, highly proliferative, ES
cells, but when these cells differentiate into embryoid bodies
Tmp expression is greatly reduced, again mimicking the
behavior of c-myc (5). Most impressively, we show
that Tmp is highly expressed in c-myc-induced
tumors. This is demonstrated for mammary tumors and T-cell lymphomas
that develop in c-myc transgenic mice (Fig. 1) and also for
c-myc-induced brain tumors, from which Tmp was
initially isolated (5). The levels of Tmp
expression in these tumors greatly exceed its expression levels in the
corresponding normal tissues. Such a dramatic degree of Tmp
activation does not appear in mammary tumors induced by other oncogenes.
Overexpression of Tmp in Rat1 cells results in increased
tumorigenicity of these cells when injected into nude mice, suggesting that Tmp function is related to cell transformation.
Combined with the high level of expression of Tmp in
c-myc-induced tumors, these findings suggest that
Tmp may play a role in the c-Myc-induced transformation
pathway. We were unable to detect significant phenotypes of the
Tmp-overexpressing cells regarding their proliferation rate
and cell-cycle-stage distribution under high-serum and low-serum conditions. We also did not detect an increase in the
anchorage-independent growth ability of the PGK-Tmp cells. It is
possible that the activity of Tmp does not affect these
characteristics in this experimental system. An additional explanation,
however, could be that Rat1 cells express the endogenous Tmp
and that this expression was elevated only ca. two- to threefold in the
transfected clones. While possibly reflecting a more physiologically
relevant system for studying Tmp function, this expression
level might not have been sufficient to induce a strong effect
regarding these characteristics. It is interesting to note that Keath
et al. (37) reported similar results for
c-myc-overexpressing rodent fibroblasts. The most prominent
phenotype of these cells was their ability to form tumors in nude mice,
while no dramatic changes were observed in the proliferation characteristics in high- or low-serum conditions and in their anchorage-independent growth ability (37). Various
phenotypes were reported, however, by other groups, probably reflecting
differences in the levels of c-myc overexpression and in
transfected cell lines (38, 55, 61).
Tmp belongs to a novel family of genes that encode membrane
glycoproteins with four transmembrane domains (5, 68, 69). All four family members display widespread expression in adult and
embryo tissues, in rodents and in humans, indicating that these
proteins probably perform a basic function in cell life (5, 68,
69). Several possible roles have been suggested for PMP22, the
most studied member of this family (65). The PMP22 protein
carries the L2/HNK1 epitope, suggesting a role in cell adhesion
(62). A role for PMP22 in cell cycle modulation has also
been suggested, based on its induction in growth-arrested cells
(44) and on the phenotypes of PMP22 overexpression, i.e., a
delay in cell cycle progression and an induction of apoptosis (29,
73, 74). These results, combined with ours, suggest that
Tmp and Pmp22 not only are inversely expressed
during proliferation and growth arrest but also modulate cell
proliferation in opposite directions.
Uncovering the c-Myc target genes and their cellular functions should
reveal which specific cellular processes are controlled by c-Myc and
how their combined action leads to the end results of cell
proliferation, transformation, or apoptosis. In recent years a number
of potential c-Myc targets have been presented, and attempts to link
their functions with the c-Myc-induced pathways have been made. Some of
these genes, such as p53 and cdc25A, encode nuclear proteins that are directly involved in cell cycle control (31, 56). Others, such as Eca39/Bcat1,
ODC, cad, and LDH-A, encode metabolic
enzymes whose function, in some cases, can be linked with cell growth
and division (4, 7, 23, 49, 52, 60). Tmp is the
first isolated c-Myc target that encodes a membrane protein, thus
extending the cellular range of c-Myc-controlled effects and adding a
possible link to cell contact processes.
The c-Myc target genes can also be tested in their ability to induce
cellular effects parallel to those induced by c-Myc itself. It has been
demonstrated, for example, that the Cdc25A, ODC,
and eIF-4E genes, when overexpressed, can induce cellular
transformation (1, 2, 32, 40). The tumorigenic effect of
Tmp overexpression places this gene among the c-Myc targets
which can mimic some of the transformation abilities of c-Myc.
 |
ACKNOWLEDGMENTS |
This research was supported by grant 3811a from The Council for
Tobacco Research, by grant 93-00017 from The U.-S.-Israel Binational
Science Foundation, Jerusalem, Israel, and by a grant from The Israel
Science Foundation, funded by The Israel Academy of Sciences and Humanities.
We thank the following investigators: Linda Z. Penn for the Rat1-MycER
cells, Ari Elson and Ian Krane for the RNA blots of tumor cell lines
from transgenic mice, Thanos Halazonetis for the MBP-Myc and MBP-Max
proteins, and Chaim Kahana for advice with the experiments. We thank
Ayellet Falcovitz and Irit Marbach for assistance with the experiments.
We thank Shoshana Klein, Amir Eden, and Yuval Dor for critical reading
of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Genetics, Institute for Life Sciences, The Hebrew University of
Jerusalem, Jerusalem 91904, Israel. Phone: 972-2-6586774. Fax:
972-2-6586975. E-mail:
nissimb{at}leonardo.ls.huji.ac.il.
 |
REFERENCES |
| 1.
|
Auvinen, M.,
A. Laine,
A. Paasinen-Sohns,
A. Kangas,
L. Kangas,
O. Saksela,
L. C. Andersson, and E. Holtta.
1997.
Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice.
Cancer Res.
57:3016-3025[Abstract/Free Full Text].
|
| 2.
|
Auvinen, M.,
A. Paasinen,
L. C. Andersson, and E. Holtta.
1992.
Ornithine decarboxylase activity is critical for cell transformation.
Nature
360:355-358[Medline].
|
| 3.
|
Ayer, D. E.,
L. Kretzner, and R. N. Eisenman.
1993.
Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity.
Cell
72:211-222[Medline].
|
| 4.
|
Bello-Fernandez, C.,
G. Packham, and J. L. Cleveland.
1993.
The ornithine decarboxylase gene is a transcriptional target of c-Myc.
Proc. Natl. Acad. Sci. USA
90:7804-7808[Abstract/Free Full Text].
|
| 5.
|
Ben-Porath, I., and N. Benvenisty.
1996.
Characterization of a tumor-associated gene, a member of a novel family of genes encoding membrane glycoproteins.
Gene
183:69-75[Medline].
|
| 6.
|
Ben-Porath, I.,
C. A. Kozak, and N. Benvenisty.
1998.
Chromosomal mapping of Tmp (Emp1), Xmp (Emp2), and Ymp (Emp3), genes encoding membrane proteins related to Pmp22.
Genomics
49:443-447[Medline].
|
| 7.
|
Benvenisty, N.,
A. Leder,
A. Kuo, and P. Leder.
1992.
An embryonically expressed gene is a target for c-Myc regulation via the c-Myc-binding sequence.
Genes Dev.
6:2513-2523[Abstract/Free Full Text].
|
| 8.
|
Benvenisty, N.,
D. M. Ornitz,
G. L. Bennett,
B. G. Sahagan,
A. Kuo,
R. D. Cardiff, and P. Leder.
1992.
Brain tumours and lymphomas in transgenic mice that carry HTLV-I LTR/c-myc and Ig/tax genes.
Oncogene
7:2399-2405[Medline].
|
| 9.
|
Ben-Yosef, T.,
O. Yanuka, and N. Benvenisty.
1996.
ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, Gcn4, in yeast.
Oncogene
13:1859-1866[Medline].
|
| 10.
|
Blackwell, T.,
J. Huang,
A. Ma,
L. Kretzner,
F. Alt,
R. Eisenman, and H. Weintraub.
1993.
Binding of Myc proteins to canonical and noncanonical DNA sequences.
Mol. Cell. Biol.
13:5216-5224[Abstract/Free Full Text].
|
| 11.
|
Blackwell, T. K.,
L. Kretzner,
E. M. Blackwood,
R. N. Eisenman, and H. Weintraub.
1990.
Sequence-specific DNA binding by the c-Myc protein.
Science
250:1149-1151[Abstract/Free Full Text].
|
| 12.
|
Blackwood, E. M., and R. N. Eisenman.
1991.
Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.
Science
251:1211-1217[Abstract/Free Full Text].
|
| 13.
|
Bolin, L.,
T. McNeil,
L. Lucian,
B. DeVaux,
K. Franz-Bacon,
D. Gorman,
S. Zurawski,
R. Murray, and T. McClanahan.
1997.
HNMP-1: a novel hematopoietic and neural membrane protein differentially regulated in neural development and injury.
J. Neurosci.
17:5493-5502[Abstract/Free Full Text].
|
| 14.
|
Cardiff, R.,
A. Leder,
A. Kuo,
P. Pattengale, and P. Leder.
1993.
Multiple tumor types appear in a transgenic mouse with the ras oncogene.
Am. J. Pathol.
142:1199-1207[Abstract].
|
| 15.
|
Cavalieri, F., and M. Goldfarb.
1987.
Growth factor-deprived BALB/c 3T3 murine fibroblasts can enter the S phase after induction of c-myc gene expression.
Mol. Cell. Biol.
7:3554-3560[Abstract/Free Full Text].
|
| 16.
|
Chance, P. F., and K. H. Fischbeck.
1994.
Molecular genetics of Charcot-Marie-Tooth disease and related neuropathies.
Hum. Mol. Genet.
3:1503-1507[Abstract].
|
| 17.
|
Chen, C., and H. Okayama.
1987.
High-efficiency transformation of mammalian cells by plasmid DNA.
Mol. Cell. Biol.
7:2745-2752[Abstract/Free Full Text].
|
| 18.
|
Chomczynski, P., and N. Sacchi.
1987.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:156-159[Medline].
|
| 19.
|
Corden, J.,
B. Wasylyk,
A. Buchwalder,
C. P. Sassone,
C. Kedinger, and P. Chambon.
1980.
Promoter sequences of eukaryotic protein-coding genes.
Science
209:1406-1414[Abstract/Free Full Text].
|
| 20.
|
Cox, A., and C. Der.
1994.
Biological assays for cellular transformation.
Methods Enzymol.
238:277-294[Medline].
|
| 21.
|
Dang, C.
1999.
c-Myc target genes involved in cell growth, apoptosis, and metabolism.
Mol. Cell. Biol.
19:1-11[Free Full Text].
|
| 22.
|
Davis, L., and T. Halazonetis.
1993.
Both the helix-loop-helix and the leucine zipper motifs of c-Myc contribute to its dimerization specificity with Max.
Oncogene
8:125-132[Medline].
|
| 23.
|
Eden, A.,
G. Simchen, and N. Benvenisty.
1996.
Two yeast homologs of ECA39, a target for c-Myc regulation, code for cytosolic and mitochondrial branched-chain amino acid aminotransferases.
J. Biol. Chem.
271:20242-20245[Abstract/Free Full Text].
|
| 24.
|
Eilers, M.,
D. Picard,
K. R. Yamamoto, and J. M. Bishop.
1989.
Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells.
Nature
340:66-68[Medline].
|
| 25.
|
Elson, A.,
C. Deng,
J. Campos-Torres,
L. Donehower, and P. Leder.
1995.
The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice.
Oncogene
11:181-190[Medline].
|
| 26.
|
Elson, A., and P. Leder.
1995.
Protein-tyrosine phosphatase epsilon. An isoform specifically expressed in mouse mammary tumors initiated by v-Ha-ras or neu.
J. Biol. Chem.
270:26116-26122[Abstract/Free Full Text].
|
| 27.
|
Evan, G.,
E. Harrington,
A. Fanidi,
H. Land,
B. Amati, and M. Bennett.
1994.
Integrated control of cell proliferation and cell death by the c-myc oncogene.
Philos. Trans. R. Soc. Lond. B. Biol. Sci.
345:269-275[Medline].
|
| 28.
|
Evan, G. I.,
A. H. Wyllie,
C. S. Gilbert,
T. D. Littlewood,
H. Land,
M. Brooks,
C. M. Waters,
L. Z. Penn, and D. C. Hancock.
1992.
Induction of apoptosis in fibroblasts by c-myc protein.
Cell
69:119-128[Medline].
|
| 29.
|
Fabbretti, E.,
P. Edomi,
C. Brancolini, and C. Schneider.
1995.
Apoptotic phenotype induced by overexpression of wild-type gas3/PMP22: its relation to the demyelinating peripheral neuropathy CMT1A.
Genes Dev.
9:1846-1856[Abstract/Free Full Text].
|
| 30.
|
Facchini, L. M., and L. Z. Penn.
1998.
The molecular role of Myc in growth and transformation: recent discoveries lead to new insights.
FASEB J.
12:633-651[Abstract/Free Full Text].
|
| 31.
|
Galaktionov, K.,
X. Chen, and D. Beach.
1996.
Cdc25 cell-cycle phosphatase as a target of c-myc.
Nature
382:511-517[Medline].
|
| 32.
|
Galaktionov, K.,
A. K. Lee,
J. Eckstein,
G. Draetta,
J. Meckler,
M. Loda, and D. Beach.
1995.
CDC25 phosphatases as potential human oncogenes.
Science
269:1575-1577[Abstract/Free Full Text].
|
| 33.
|
Gorman, C. M.,
L. F. Moffat, and B. H. Howard.
1982.
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.
Mol. Cell. Biol.
2:1044-1051[Abstract/Free Full Text].
|
| 34.
|
Grandori, C., and R. Eisenman.
1997.
Myc target genes.
Trends Biochem. Sci.
22:177-181[Medline].
|
| 35.
|
Grandori, C.,
J. Mac,
F. Siebelt,
D. Ayer, and R. Eisenman.
1996.
Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites in vivo.
EMBO J.
15:4344-4357[Medline].
|
| 36.
|
Iyer, V., and K. Struhl.
1995.
Poly(dA:dT), a ubiquitous promoter element that stimulates transcription via its intrinsic DNA structure.
EMBO J.
14:2570-2579[Medline].
|
| 37.
|
Keath, E. J.,
P. G. Caimi, and M. D. Cole.
1984.
Fibroblast lines expressing activated c-myc oncogenes are tumorigenic in nude mice and syngeneic animals.
Cell
39:339-348[Medline].
|
| 38.
|
Kelekar, A., and M. Cole.
1986.
Tumorigenicity of fibroblast lines expressing the adenovirus E1a, cellular p53, or normal c-myc genes.
Mol. Cell. Biol.
6:7-14[Abstract/Free Full Text].
|
| 39.
|
Krane, I., and P. Leder.
1996.
NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice.
Oncogene
12:1781-1788[Medline].
|
| 40.
|
Lazaris-Karatzas, A.,
K. Montine, and N. Sonenberg.
1990.
Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap.
Nature
345:544-547[Medline].
|
| 41.
|
Lee, W.,
A. Haslinger,
M. Karin, and R. Tjian.
1987.
Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40.
Nature
325:368-372[Medline].
|
| 42.
|
Littlewood, T.,
D. Hancock,
P. Danielian,
M. Parker, and G. Evan.
1995.
A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins.
Nucleic Acids Res.
23:1686-1690[Abstract/Free Full Text].
|
| 43.
|
Lobsiger, C.,
J. Magyar,
V. Taylor,
P. Wulf,
A. Welcher,
Amgen EST Program, and U. Suter.
1996.
Identification and characterization of a cDNA and the structural gene encoding the mouse epithelial membrane protein-1.
Genomics
36:379-387[Medline].
|
| 44.
|
Manfioletti, G.,
M. E. Ruaro,
G. Del Sal,
L. Philipson, and C. Schneider.
1990.
A growth arrest-specific (gas) gene codes for a membrane protein.
Mol. Cell. Biol.
10:2924-2930[Abstract/Free Full Text].
|
| 45.
|
Marcu, K. B.,
S. A. Bossone, and A. J. Patel.
1992.
myc function and regulation.
Annu. Rev. Biochem.
61:809-860[Medline].
|
| 46.
|
Marhin, W.,
S. Chen,
L. Facchini,
J. Fornace, and L. Penn.
1997.
Myc represses the growth arrest gene gadd45.
Oncogene
14:2825-2834[Medline].
|
| 47.
|
Marvin, K. W.,
W. Fujimoto, and A. M. Jetten.
1995.
Identification and characterization of a novel squamous cell-associated gene related to PMP22.
J. Biol. Chem.
270:28910-28916[Abstract/Free Full Text].
|
| 48.
|
Meichle, A.,
A. Philipp, and M. Eilers.
1992.
The functions of Myc proteins.
Biochim. Biophys. Acta
1114:129-146[Medline].
|
| 49.
|
Miltenberger, R.,
K. Sukow, and P. Farnham.
1995.
An E-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants.
Mol. Cell. Biol.
15:2527-2535[Abstract].
|
| 50.
|
Muller, W. J.,
E. Sinn,
P. K. Pattengale,
R. Wallace, and P. Leder.
1988.
Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.
Cell
54:105-115[Medline].
|
| 51.
|
Patel, P. I., and J. R. Lupski.
1994.
Charcot-Marie-Tooth disease: a new paradigm for the mechanism of inherited disease.
Trends Genet.
10:128-133[Medline].
|
| 52.
|
Pena, A.,
C. D. Reddy,
S. Wu,
N. J. Hickok,
E. P. Reddy,
G. Yumet,
D. R. Soprano, and K. J. Soprano.
1993.
Regulation of human ornithine decarboxylase expression by the c-Myc.Max protein complex.
J. Biol. Chem.
268:27277-27285[Abstract/Free Full Text].
|
| 53.
|
Potter, H.,
L. Weir, and P. Leder.
1984.
Enhancer-dependent expression of human kappa immunoglobulin genes introduced into pre-B lymphocytes by electroporation.
Proc. Natl. Acad. Sci. USA
81:7161-7165[Abstract/Free Full Text].
|
| 54.
|
Prendergast, G. C., and E. B. Ziff.
1992.
A new bind for Myc.
Trends Genet.
8:91-96[Medline].
|
| 55.
|
Ray, R.,
S. Thomas, and D. Miller.
1989.
Mouse fibroblasts transformed with the human c-myc gene express a high level of mRNA but a low level of c-myc protein and are non-tumorigenic in nude mice.
Oncogene
4:593-600[Medline].
|
| 56.
|
Reisman, D.,
N. B. Elkind,
B. Roy,
J. Beamon, and V. Rotter.
1993.
c-Myc transactivates the p53 promoter through a required downstream CACGTG motif.
Cell Growth Differ.
4:57-65[Abstract].
|
| 57.
|
Ruegg, C. L.,
H. Y. Wu,
F. F. Fagnoni,
E. G. Engleman, and R. Laus.
1996.
B4B, a novel growth-arrest gene, is expressed by a subset of progenitor/pre-B lymphocytes negative for cytoplasmic mu-chain.
J. Immunol.
157:72-80[Abstract].
|
| 58.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 59.
|
Schiemann, S.,
M. Ruckels,
L. H. Engelholm,
M. Schwirzke,
N. Brunner, and U. H. Weidle.
1997.
Differential gene expression in human mammary carcinoma cells: identification of a new member of a receptor family.
Anticancer Res.
17:13-20[Medline].
|
| 60.
|
Shim, H.,
C. Dolde,
B. C. Lewis,
C. S. Wu,
G. Dang,
R. A. Jungmann,
R. Dalla-Favera, and C. V. Dang.
1997.
c-Myc transactivation of LDH-A: implications for tumor metabolism and growth.
Proc. Natl. Acad. Sci. USA
94:6658-6663[Abstract/Free Full Text].
|
| 61.
|
Small, M. B.,
N. Hay,
M. Schwab, and J. M. Bishop.
1987.
Neoplastic transformation by the human gene N-myc.
Mol. Cell. Biol.
7:1638-1645[Abstract/Free Full Text].
|
| 62.
|
Snipes, G. J.,
U. Suter, and E. M. Shooter.
1993.
Human peripheral myelin protein-22 carries the L2/HNK-1 carbohydrate adhesion epitope.
J. Neurochem.
61:1961-1964[Medline].
|
| 63.
|
Stewart, T. A.,
P. K. Pattengale, and P. Leder.
1984.
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes.
Cell
38:627-637[Medline].
|
| 64.
|
Stone, J.,
T. de Lange,
G. Ramsay,
E. Jakobovits,
J. M. Bishop,
H. Varmus, and W. Lee.
1987.
Definition of regions in human c-myc that are involved in transformation and nuclear localization.
Mol. Cell. Biol.
7:1697-1709[Abstract/Free Full Text].
|
| 65.
|
Suter, U., and G. J. Snipes.
1995.
Peripheral myelin protein 22: facts and hypotheses.
J. Neurosci. Res.
40:145-151[Medline].
|
| 66.
|
Suter, U.,
G. J. Snipes,
S. R. Schoener,
A. A. Welcher,
S. Pareek,
J. R. Lupski,
R. A. Murphy,
E. M. Shooter, and P. I. Patel.
1994.
Regulation of tissue-specific expression of alternative peripheral myelin protein-22 (PMP22) gene transcripts by two promoters.
J. Biol. Chem.
269:25795-25808[Abstract/Free Full Text].
|
| 67.
|
Tavtigian, S. V.,
S. D. Zabludoff, and B. J. Wold.
1994.
Cloning of mid-G1 serum response genes and identification of a subset regulated by conditional myc expression.
Mol. Biol. Cell
5:375-388[Abstract].
|
| 68.
|
Taylor, V., and U. Suter.
1996.
Epithelial membrane protein-2 and epithelial membrane protein-3: two novel members of the peripheral myelin protein 22 gene family.
Gene
175:115-120[Medline].
|
| 69.
|
Taylor, V.,
A. A. Welcher,
Amgen EST Program, and U. Suter.
1995.
Epithelial membrane protein-1, peripheral myelin protein 22, and lens membrane protein 20 define a novel gene family.
J. Biol. Chem.
270:28824-28833[Abstract/Free Full Text].
|
| 70.
|
Wagner, A. J.,
C. Meyers,
L. A. Laimins, and N. Hay.
1993.
c-Myc induces the expression and activity of ornithine decarboxylase.
Cell Growth Differ.
4:879-883[Abstract].
|
| 71.
|
Wulf, G.,
C. Adra, and B. Lim.
1993.
Inhibition of hematopoietic development from embryonic stem cells by antisense vav RNA.
EMBO J.
12:5065-5074[Medline].
|
| 72.
|
Yang, W.,
H. Wang, and L. Fliegel.
1996.
Regulation of Na+/H+ exchanger gene expression. Role of a novel poly(dA · dT) element in regulation of the NHE1 promoter.
J. Biol. Chem.
271:20444-20449[Abstract/Free Full Text].
|
| 73.
|
Zoidl, G.,
K. S. Blass,
D. D'Urso,
C. Schmalenbach, and H. W. Muller.
1995.
Retroviral-mediated gene transfer of the peripheral myelin protein PMP22 in Schwann cells: modulation of cell growth.
EMBO J.
14:1122-1128[Medline].
|
| 74.
|
Zoidl, G.,
D. D'Urso,
K. S. Blass,
C. Schmalenbach,
R. Kuhn, and H. W. Muller.
1997.
Influence of elevated expression of rat wild-type PMP22 and its mutant PMP22Trembler on cell growth of NIH3T3 fibroblasts.
Cell Tissue Res.
287:459-470[Medline].
|
Molecular and Cellular Biology, May 1999, p. 3529-3539, Vol. 19, No. 5
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Bredel, M., Bredel, C., Juric, D., Harsh, G. R., Vogel, H., Recht, L. D., Sikic, B. I.
(2005). Functional Network Analysis Reveals Extended Gliomagenesis Pathway Maps and Three Novel MYC-Interacting Genes in Human Gliomas. Cancer Res.
65: 8679-8689
[Abstract]
[Full Text]
-
Wadehra, M., Goodglick, L., Braun, J.
(2004). The Tetraspan Protein EMP2 Modulates the Surface Expression of Caveolins and Glycosylphosphatidyl Inositol-linked Proteins. Mol. Biol. Cell
15: 2073-2083
[Abstract]
[Full Text]
-
Gazit, R., Krizhanovsky, V., Ben-Arie, N.
(2004). Math1 controls cerebellar granule cell differentiation by regulating multiple components of the Notch signaling pathway. Development
131: 903-913
[Abstract]
[Full Text]
-
Norman, B., Davis, J., Piatigorsky, J.
(2004). Postnatal Gene Expression in the Normal Mouse Cornea by SAGE. IOVS
45: 429-440
[Abstract]
[Full Text]
-
Taxman, D. J., MacKeigan, J. P., Clements, C., Bergstralh, D. T., Ting, J. P-Y.
(2003). Transcriptional Profiling of Targets for Combination Therapy of Lung Carcinoma with Paclitaxel and Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase Inhibitor. Cancer Res.
63: 5095-5104
[Abstract]
[Full Text]
-
Yin, X., Grove, L., Rogulski, K., Prochownik, E. V.
(2002). Myc Target in Myeloid Cells-1, a Novel c-Myc Target, Recapitulates Multiple c-Myc Phenotypes. J. Biol. Chem.
277: 19998-20010
[Abstract]
[Full Text]
-
Yin, X.-Y., Grove, L., Datta, N. S., Katula, K., Long, M. W., Prochownik, E. V.
(2001). Inverse Regulation of Cyclin B1 by c-Myc and p53 and Induction of Tetraploidy by Cyclin B1 Overexpression. Cancer Res.
61: 6487-6493
[Abstract]
[Full Text]
-
Wood, L. J., Mukherjee, M., Dolde, C. E., Xu, Y., Maher, J. F., Bunton, T. E., Williams, J. B., Resar, L. M. S.
(2000). HMG-I/Y, a New c-Myc Target Gene and Potential Oncogene. Mol. Cell. Biol.
20: 5490-5502
[Abstract]
[Full Text]